Quick Links
Contact us
Submit a medical question on an Otsuka product.
To discuss a medical inquiry on an Otsuka product, please call 1-800-441-67631-800-441-6763.
To report an adverse event or a product quality complaint, please call 1-800-438-99271-800-438-9927.
Featured news
New Report Shows Nearly Half of U.S. States Are on the Threshold of a Caregiving Emergency
In the 32 states with predominantly rural populations, unpaid family caregivers contribute over $375 billion in labor, yet a shortage of healthcare workers makes it challenging for families to access necessary support.Dementia care is driving a significant portion of the national family caregiving valuation, contributing to over $340 billion of labor, especially those in states with aging and high-risk populations. This new analysis found that even a 10% increase in dementia care hours would add another $62 billion in unpaid labor nationwide.
Otsuka Files Biologics License Application (BLA) for Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy
NephrologyOtsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceutical Co., Ltd. (Otsuka) announce the filing of a Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA) for sibeprenlimab, an investigational monoclonal antibody that selectively inhibits the activity of APRIL (A PRoliferation-Inducing Ligand) in adults with immunoglobulin A nephropathy (IgAN).
Otsuka Announces FDA Plans to Host an Advisory Committee Meeting to Discuss the sNDA for Brexpiprazole in Combination with Sertraline for the Treatment of Adults with Post-Traumatic Stress Disorder (PTSD)
NeuroscienceOtsuka America Pharmaceutical, Inc., (OAPI) and Otsuka Pharmaceutical, Co., Ltd. (Otsuka) announce that the U.S. Food and Drug Administration (FDA) plans to host a Psychopharmacologic Drugs Advisory Committee (PDAC) meeting to seek input on issues related to the Supplemental New Drug Application (sNDA) for brexpiprazole in combination with sertraline for the treatment of adults with post-traumatic stress disorder (PTSD).